Advertisements

Sertralina Ecar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Sertralina Ecar

Sertralina Ecar is a prescription-only medicine whose identity is rooted in its highly selective action on the central nervous system, positioning it as a fundamental tool in modern psychiatric pharmacotherapy. The drug's general purpose is to support mood regulation and emotional equilibrium by addressing chemical signaling imbalances in the brain.

Property Description
Active ingredient Sertraline (hydrochloride)
Form Oral solid dosage form (Tablet)
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Psychiatric pharmacotherapy, mood regulation
Origin Synthetic compound

What Type of Medicine is Sertralina Ecar?

Sertralina Ecar is an established antidepressant that belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class, a specialized group of psychotropic agents. Its status as an SSRI differentiates it from older generations of mood-altering medications by its highly targeted action on the serotonin system. This medicine is clinically recognized for its role in supporting individuals through periods of persistent low mood or excessive worry, providing pharmacological support for the management of various mental health disorders. The efficacy of sertraline in these areas is clinically recognized.

Composition, Form, and Origin of Sertraline

The active ingredient in this single-active-ingredient product is the synthetic compound sertraline, typically formulated as the hydrochloride salt for stability. Sertraline is a synthetic derivative of naphthalenamine, confirming its origin as a chemically manufactured compound. Sertralina Ecar is designed for oral administration as an oral solid dosage form, most commonly a film-coated tablet, which utilizes pharmaceutical excipients to ensure stability and proper delivery of the drug necessary for consistent long-term treatment.

The General Principle of Sertraline’s Action

The fundamental mechanism principle of sertraline is inhibition of neuronal uptake of serotonin. This highly focused action, known as serotonin reuptake inhibition, involves preventing the nerve cells from quickly drawing the neurotransmitter serotonin back into the cell, thereby increasing its functional availability in the brain's communication pathways. This specific neurotransmitter modulation serves the general benefit of stabilizing those nerve pathways involved in emotion and mood, thus facilitating improvement in persistent psychological distress.

Regulatory References

  1. Sertraline - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Sertralina Ecar?

Adverse Reaction Scope

The official safety documents for Sertralina Ecar classify possible adverse reactions based on how frequently they are reported in clinical use. These documented effects are grouped into standard System-Organ Classes, covering areas such as Gastrointestinal Disorders, Nervous System Disorders, and Psychiatric Disorders.

Frequency Classification Representative Adverse Reactions (Abridged)
Very Common (ge 1/10) Insomnia, headache, dizziness, nausea, diarrhoea, dry mouth, ejaculation failure/disorders.
Common (ge 1/100 to < 1/10) Tremor, somnolence, dyspepsia, increased sweating, palpitations, and decreased libido.
Uncommon / Rare Includes reactions such as hallucination, aggression, haemorrhagic events, and seizures.

Serious Adverse Reactions and Safety Constraints

The prescribing information highlights specific serious adverse reactions. These include the potential for Serotonin Syndrome, Neuroleptic Malignant Syndrome (NMS)-like events, and an increased risk of bleeding or haemorrhagic events. Furthermore, Activation of Mania or Hypomania and Angle-Closure Glaucoma are documented safety concerns.

Population-Specific and Contextual Safety Notes

Safety constraints noted in regulatory documents specify certain risks for particular populations. The risk of Hyponatraemia (low sodium levels) is noted as a particular concern in older adults. For patients with hepatic impairment, the drug’s clearance is reduced, and use is generally avoided in severe hepatic impairment. Official labeling also notes that adverse reactions such as anxiety and nervousness may be more frequently observed at the start of treatment or following a dosage change, and that symptoms can occur upon the abrupt cessation of treatment. The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs).

Advertisements

Overdose and Emergency Response

Sertralina Ecar Overdose and when to seek help

Domain Official Regulatory Statement
Documented overdose presentations Common reported clinical manifestations include drowsiness, tremor, nausea, vomiting, dizziness, tachycardia (rapid heartbeat), agitation, and diarrhea.
Physiological systems affected The central nervous system, cardiovascular system, and neuromuscular system may be affected, with severe outcomes involving Seizures, Coma, and QRS/QTc interval prolongation.
Dose-related or exposure-related factors The risk of severe, life-threatening outcomes, including Serotonin Syndrome, is significantly elevated in cases of multiple drug overdosage involving other serotonergic agents or alcohol.
Emergency-response statements Seek immediate medical attention. Contact a Poison Center or a medical toxicologist for overdosage management. Treatment is confined to supportive care and close observation of vital signs.
Classification Aspect Official Regulatory Statement
Severity classification Life-threatening outcomes include Serotonin Syndrome and seizures. No specific treatment to reverse the effects of sertraline exists.
When immediate medical help is required Call emergency services (such as 911) immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Resulting Overdose Structure

Official Overdose Statements:

  • An overdosage may present with drowsiness, tremor, tachycardia, and gastrointestinal distress.
  • Severe outcomes reported include Serotonin Syndrome, seizures, and cardiovascular toxicity.
  • No specific antidote is documented in official labeling; management involves supportive treatment and monitoring of cardiac function.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Sertralina Ecar overdose profile by classifying the expected clinical manifestations and explicitly highlighting the potential for severe, life-threatening complications. This profile mandates that urgent medical help must be sought if any severe signs, such as seizures or loss of consciousness, are observed. The official guidance emphasizes management through supportive care due to the absence of a known specific reversal agent.

Advertisements

Therapeutic Uses of Sertralina Ecar

What Sertralina Ecar Treats: Main Uses and Benefits

Sertralina Ecar is a relevant therapeutic option applied across key mental health domains to provide supportive symptom management. It generally contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Sertralina Ecar is commonly used to help with conditions characterized by periods of persistent low mood like Major Depressive Disorder, and is used for managing severe anxiety and fear states such as Panic Disorder, Social Anxiety Disorder, Post-Traumatic Stress Disorder (PTSD), and the complex symptom clusters of Obsessive-Compulsive Disorder (OCD). It also plays a role in managing the severe cyclical mood symptoms of Premenstrual Dysphoric Disorder (PMDD). This supportive relief contributes to improved day-to-day comfort during symptomatic periods, and the medication is often applied when symptoms become temporarily overwhelming.

Quick Fact: Relief for Intrusive Thoughts

Sertralina Ecar is considered relevant in contexts marked by the functional strain of intrusive thoughts and ritualized actions common in OCD. Its primary benefit is to assist in stabilizing the emotional baseline, which supports the patient's capacity for engagement with routine life.

Advertisements

Eligibility and Restrictions for Use

The eligibility for using Sertralina Ecar is strictly defined by regulatory documents based on absolute prohibitions, age, and pre-existing health conditions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients with known hypersensitivity to sertraline, those receiving Monoamine Oxidase Inhibitors (MAOIs), or those taking pimozide are strictly prohibited from use.
Age-related eligibility rules Adults are approved for all labeled uses. Children and adolescents (aged 6–17 years) are approved only for the treatment of Obsessive-Compulsive Disorder (OCD). Use is not established in children younger than six years.
Condition-specific eligibility rules Use is not recommended in patients with severe hepatic impairment due to reduced clearance and a lack of clinical data. Caution is required for those with a history of mania or hypomania, unstable epilepsy, or angle-closure glaucoma.
Physiological Status Use is generally not recommended during pregnancy (especially the third trimester). Use during lactation requires individual physician assessment.

Resulting Eligibility Structure

Regulatory documentation establishes eligibility by defining absolute exclusions (MAOIs, pimozide), limiting pediatric use to a single condition (OCD), and requiring conditional use or avoidance in cases of severe liver impairment, historical mania, or epilepsy.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sertralina Ecar can interact with several other medicines and substances, primarily by affecting the amount of serotonin in the body, which can lead to a serious condition known as Serotonin Syndrome. It can also affect the body’s ability to clot blood, increasing the risk of bleeding.

Contraindicated Combinations

Do not use Sertralina Ecar with the following:

  • Monoamine Oxidase Inhibitors (MAOIs), including the antidepressant phenelzine and the antibiotic linezolid. This combination is strictly forbidden due to the risk of Serotonin Syndrome. A mandatory “wash-out” period is required when switching between Sertralina Ecar and an MAOI: wait at least 14 days after stopping the MAOI before starting Sertralina Ecar, and wait at least 7 days after stopping Sertralina Ecar before starting an MAOI.
  • Pimozide, a medication used for Tourette’s disorder, as Sertralina Ecar can significantly increase its concentration in the body.
  • Disulfiram, if using the liquid oral solution form of Sertralina Ecar, due to the alcohol content in the solution.

Combinations Requiring Caution

Close medical monitoring is needed when Sertralina Ecar is combined with:

  • Other Serotonergic Agents: Medicines that also increase serotonin, such as migraine treatments (triptans), other antidepressants, tramadol, and the herbal supplement St John's Wort. This is to manage the risk of Serotonin Syndrome.
  • Medicines that increase the risk of bleeding: This includes blood thinners (anticoagulants) like warfarin and medicines that affect platelets, such as aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).
  • Phenytoin (an anti-seizure medicine) and certain drugs metabolized by the CYP2D6 enzyme (e.g., desipramine), as Sertralina Ecar can increase their concentrations.

Other Interactions

  • It is generally not recommended to consume alcohol while taking Sertralina Ecar.
Advertisements

Mechanism of Action

Selective Targeting of the Serotonin Transporter (SERT)

The primary action of sertraline is the selective inhibition of the Serotonin Transporter (SERT), the reuptake protein on the presynaptic nerve terminal. By binding to SERT, the molecule prevents the rapid clearance of the neurotransmitter serotonin (5-HT) from the synaptic cleft, leading to an immediate increase in 5-HT concentration in the space between neurons. This targeted molecular event directly alters the signaling dynamics of the serotonergic system.


Mechanism of Delayed Neuroadaptive Signaling

The full physiological effect requires time because the initial increase in serotonin triggers a temporary inhibitory feedback loop via presynaptic autoreceptors. The sustained presence of the drug is necessary to drive a neuroadaptive cascade, causing the eventual downregulation and desensitization of these inhibitory receptors. This process results in the cessation of autoreceptor-mediated feedback inhibition on 5-HT release, enabling a sustained enhancement of serotonergic signaling in pathways governing affective processing.


Biological Constraints on Mechanism Efficacy

The function of the mechanism is inherently constrained by the time required for cellular neuroadaptation (the autoreceptor desensitization process) and by genetic variability in the target protein. Genetic polymorphisms in the SLC6A4 gene, which codes for the SERT protein, can create physiological targets that are less available or less responsive to sertraline, creating individual differences in the degree of altered serotonergic signaling.

Advertisements

Dosage and Administration Information

How Sertralina Ecar is Used: Official Administration Guidelines

Sertralina Ecar (sertraline) is officially administered solely via the oral route, available in both tablets (typically 25 mg, 50 mg, and 100 mg strengths) and an oral solution/concentrate. The entire daily dose is formalized for once-daily (qDay) administration, which can be taken consistently in either the morning or the evening.

Dosage and Scheduling Principles

Initial dosing varies by indication; for certain conditions like Major Depressive Disorder, the starting dose is generally 50 mg per day, while for conditions like Panic Disorder, the starting dose is typically 25 mg per day. The maximum recommended daily dose for most adults is 200 mg. Increases in dosage must be carried out gradually, in increments of 25 mg to 50 mg, separated by intervals of not less than one week to follow the established titration schedule. Steady-state plasma concentrations of the medicine are usually achieved after approximately one week of once-daily use.

Administration Requirements

Administration Factor Official Instruction
Tablet Intake May be consumed with or without food.
Oral Concentrate Use Must be measured with the provided dropper and immediately diluted in 4 ounces of specified liquids (water, ginger ale, lemon/lime soda, lemonade, or orange juice only).
Missed Dose If a dose is missed, the instruction is to skip the missed dose and resume the schedule at the next regularly scheduled time; double-dosing is not supported.
Special Populations Patients with hepatic impairment are often advised to begin with a lower or less frequent dose. Pediatric use for Obsessive-Compulsive Disorder (OCD) begins at 25 mg (ages 6-12) or 50 mg (ages 13-17).

These standardized instructions define the administration protocol, from initiation through the maintenance phase.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Sertralina Ecar

Evidence for Major Depressive Disorder (MDD)

Short-term placebo-controlled Randomized Controlled Trials (RCTs) were used in research exploring how symptoms change over time in adult populations, monitoring symptom intensity and clinical impression. Maintenance treatment research reported a pattern of longer observed time until recurrence for individuals with a history of multiple episodes when compared against placebo. Sample sizes were modest in certain trials focusing on medically complex patients, suggesting evidence quality may vary across studies depending on the specific group observed.

Evidence for Obsessive-Compulsive Disorder (OCD)

Controlled trials were used in research exploring short-term symptom changes in adults and in pediatric patients. Long-term maintenance trials were evaluated in treatment-responsive patients to see how symptoms evolved in the observed populations over extended periods of follow-up. A recognized limitation is the uncertainty around the ideal dose for long-term symptom management; research exploring how outcomes associated with higher doses compare to standard doses is not fully established.

Evidence for Panic, Social Anxiety, and Post-Traumatic Stress Disorders

Short-term placebo-controlled RCTs were used in research exploring episodic or acute changes related to these conditions, monitoring panic attack frequency and specific symptom clusters in PTSD. Studies explored correlations between treatment and the measured number of reported panic attacks over the study period. Follow-up durations were limited in many of the initial acute treatment trials, and evidence is limited for children and adolescents with PTSD due to early trial termination.

Long-Term Studies and Durability of Follow-up

This section summarizes the structure of double-blind, randomized maintenance trials that monitored recurrence and relapse rates. Research does not establish a universal, precise length of time that continuation may be observed to prevent recurrence; long-term effects are not fully established beyond the observation period of the controlled trials.

Research in Specific Patient Populations

The available evidence was evaluated in groups beyond the general adult population, including children, adolescents, older adults, and individuals with various co-morbid conditions. Findings in some of these groups were mixed or data for certain groups remain insufficient due to small sample sizes. Some studies indicate that reported outcomes and dropout rates may differ when comparing men and women with chronic depression.

Documented Research Gaps and Uncertainties

Certainty remains low in understanding the ideal duration of treatment required to prevent recurrence in all patient groups. Comparative evidence is lacking in terms of direct, long-term head-to-head trials against other medications in the same class. Overall, data are still emerging for complex clinical situations and specific medical co-morbidities, and research is ongoing to provide further insight into these areas.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sertralina Ecar (FAQ)


Q: How quickly does Sertralina Ecar start working?

Studies and official information indicate that the drug substance typically achieves steady-state concentrations in the bloodstream after approximately one week of once-daily use. However, the full physiological effect, which involves a necessary neuroadaptive process, requires more time. Due to the mechanism of action, the therapeutic onset is not immediate.


Q: What is the typical time frame to notice an effect from Sertralina Ecar?

The therapeutic effect from Sertralina Ecar may not be observed until several weeks of treatment have been completed. Official documentation suggests that initial responses typically precede the achievement of the full treatment benefit. This time frame reflects the body's neuroadaptive process required to achieve altered signaling dynamics.


Q: What happens if I miss a dose of Sertralina Ecar?

The official regulatory guidance for a missed dose describes skipping it entirely and resuming the schedule at the next regularly scheduled time. Regulatory guidance specifies that taking a double dose to make up for the missed one is not supported.


Q: How long does Sertralina Ecar stay in your system after stopping?

The active ingredient, sertraline, has an elimination half-life of about 26 hours. However, the body processes a substance called desmethylsertraline, which has a longer half-life, reported to be approximately 62 to 104 hours. This means the substance and its active metabolites may remain in the body for several days after the last dose.


Q: Is a metallic taste a known side effect of Sertralina Ecar?

Official safety listings document that a change in taste perception, described as taste perversion, has been reported as an adverse reaction. This effect is generally classified in the Uncommon frequency category, meaning it affects less than 1 in 100 people.


Q: What should I know about taking Sertralina Ecar and driving?

Official labeling contains a clear warning that Sertralina Ecar may affect the mental and physical abilities needed to drive or operate dangerous machinery. This is because side effects like dizziness, tremor, or somnolence (drowsiness) are documented in the official safety information. This information is provided to allow for informed decision-making regarding activities requiring full alertness.


Q: Can Sertralina Ecar be taken with pain relievers like ibuprofen?

Caution is advised in regulatory documents when Sertralina Ecar is combined with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. The combination carries the potential for an increased risk of bleeding or haemorrhagic events. This concern is described in the official drug interaction section.


Q: Does Sertralina Ecar affect liver function?

Official warnings note that Sertralina Ecar is processed through the liver. Caution is advised for individuals with existing liver disease (hepatic impairment), and use is generally avoided in cases of severe impairment due to reduced clearance. Regulatory safety data also document that increases in liver enzyme levels have been reported.


Q: Why is Sertralina Ecar sometimes taken for premenstrual dysphoric disorder (PMDD)?

Official regulatory documents list the treatment of Premenstrual Dysphoric Disorder (PMDD) as an approved use (labeled indication) for the medicine. This indication is supported by clinical evidence provided to regulatory bodies.


Q: What is the maximum dose of Sertralina Ecar studied in research?

The upper limit of the maximum recommended daily dose for most adults is 200 mg. This is the highest dose established and studied in clinical trials for the medicine's approved uses.


Q: Is Sertralina Ecar the same as Zoloft?

Sertralina Ecar contains the active ingredient sertraline. Zoloft is simply the brand name under which the active ingredient sertraline was originally marketed in some regions. Generic and brand-name products contain the same active ingredient.


Q: Is it common to feel worse when first starting Sertralina Ecar?

Official labeling notes that adverse reactions such as anxiety and nervousness may be more frequently observed at the beginning of treatment or following a change in dosage. This may be related to the body adjusting to the medicine; official labeling suggests these reactions are more frequently observed at the start of treatment.


Q: Does Sertralina Ecar cause weight gain?

The official safety documents list both weight gain and weight decrease as adverse reactions that have been documented in clinical trials. Both are categorized in the Common frequency classification, meaning they affect less than 1 in 10 people.


Q: Is Sertralina Ecar considered a controlled substance?

The active ingredient, sertraline, has been classified by regulatory bodies as a non-controlled substance. This means the drug is not categorized by the same strict controls as certain other medications with a potential for abuse.


Q: Can Sertralina Ecar be used long-term?

Clinical studies supporting the drug's use have included long-term maintenance trials. These trials were designed to assess changes in symptoms and recurrence rates in treatment-responsive patients over extended observation periods.


Q: Is Sertralina Ecar addictive?

Official regulatory documents state that the drug has no recognized potential for abuse. However, it is noted that certain symptoms can occur upon the abrupt cessation of treatment. Cessation of treatment is typically carried out under professional guidance.


Q: Can Sertralina Ecar be crushed or chewed?

The tablets are intended to be swallowed whole and should not be crushed or chewed. The oral concentrate solution, which is also available, must be measured using the provided dropper and immediately diluted in one of the specified liquids before consuming.


Q: Do generics of Sertralina Ecar work the same as the brand name?

Regulatory bodies consider generic drug products to be therapeutically equivalent to their brand-name counterparts. This means they contain the same active ingredient and are expected to have the same clinical effect and safety profile.


Q: Why do doctors prescribe Sertralina Ecar for conditions other than depression?

Official labeling lists multiple approved uses for the medicine beyond depression. These approved uses include Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, and Premenstrual Dysphoric Disorder (PMDD).


Q: Is Sertralina Ecar safe for older adults?

Official regulatory documents specifically address use in older adults. These documents note an increased risk of Hyponatraemia (abnormally low sodium levels) as a particular safety concern in this population.


Q: Are there different forms of Sertralina Ecar (e.g., tablet, liquid)?

The medicine is available in more than one form for oral administration. The official dosage forms include film-coated tablets in various strengths and an oral solution or concentrate.


Q: What are the most common reasons people discontinue Sertralina Ecar?

Clinical trial data indicate that the most common reasons for participants discontinuing the drug due to adverse events included gastrointestinal effects such as nausea and diarrhea. Other common reasons included insomnia, dry mouth, and ejaculation failure.


Q: Does Sertralina Ecar interact with birth control pills?

Official regulatory documents regarding drug interactions contain no explicit warning or contraindication for the co-administration of sertraline with standard oral contraceptives (birth control pills). The official product safety information does not contain an explicit warning regarding this interaction.


Q: What research evidence supports the use of Sertralina Ecar?

Regulatory approval is based on clinical evidence derived from controlled trials. These include short-term placebo-controlled Randomized Controlled Trials (RCTs) to assess acute effects and long-term maintenance trials to monitor recurrence and relapse rates.


Q: Is Sertralina Ecar generally well-tolerated?

Tolerability is assessed based on the frequency of reported adverse reactions. Official documents list effects such as insomnia, nausea, and headache among the most frequently reported, categorized as Very Common (affecting 1 in 10 people or more).


Q: How is Sertralina Ecar different from tricyclic antidepressants?

Sertralina Ecar is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This means its primary action is highly selective for the serotonin transporter. This focused mechanism differentiates it from tricyclic antidepressants, which are an older class of drugs that affect a wider range of neurotransmitters.


Q: Can men and women experience different side effects from Sertralina Ecar?

Official safety data confirms that certain adverse reactions are specific to sex, such as ejaculation failure, which is reported in men. Research summaries also indicate that overall outcomes and dropout rates may differ when comparing men and women in studies of chronic depression.


Q: Does Sertralina Ecar interact with over-the-counter cold medicines?

Official regulatory documents advise caution with co-administration of other serotonergic agents. Some cold medicines contain ingredients like dextromethorphan, which can increase serotonin levels, creating a theoretical risk of interaction that necessitates caution.


Q: Can Sertralina Ecar lead to easy bruising?

Official safety documents list the potential for an increased risk of bleeding or haemorrhagic events. This includes common occurrences like ecchymosis (easy bruising), which is classified in the Uncommon frequency category (affecting less than 1 in 100 people).


Q: Is it necessary to inform a dentist about taking Sertralina Ecar?

Warnings in the official product information about the increased risk of bleeding or haemorrhagic events suggests that disclosure to medical professionals, including dentists, may be relevant during the planning of procedures.


Q: Why do some people refer to Sertralina Ecar as a serotonin reuptake inhibitor?

The medicine is classified by its fundamental mechanism principle, which is the inhibition of the neuronal uptake of serotonin. Because the drug prevents the reabsorption (reuptake) of serotonin, the descriptive term serotonin reuptake inhibitor accurately reflects its specific action on the brain's chemistry.


Q: Can Sertralina Ecar cause vivid dreams?

Official safety documents list nightmares as an adverse reaction in the Common frequency classification (affecting less than 1 in 10 people). This report indicates that the medicine can impact sleep and dream quality.


Q: Does Sertralina Ecar affect the ability to concentrate?

Official safety documents list disturbance in attention as an adverse reaction in the Common frequency classification (affecting less than 1 in 10 people). This finding suggests that the medicine has the potential to impact a person's ability to focus.


Q: What is the role of Sertralina Ecar in treating panic disorder?

The drug is officially indicated for the treatment of Panic Disorder in regulatory documents. Clinical studies demonstrated that the drug was effective in observed populations for the reduction of the frequency of panic attacks.

Advertisements

How should Sertralina Ecar be stored and disposed of?

Official Storage and Disposal Requirements

Sertralina Ecar (sertraline tablets) must be stored and disposed of according to the explicit instructions defined by governmental regulatory agencies to ensure product quality and environmental safety.

Storage Classification Requirement
Temperature Store at controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF) [FDA Labeling].
Protection Keep in the original container, tightly closed, and protected from excessive heat, moisture, and light [MedlinePlus].
Safety Keep out of the sight and reach of children (mandatory safety instruction) [EMA/SmPC].

For disposal, the medicine is not on the FDA flush list and must not be flushed down the toilet. The preferred method for discarding unused or expired Sertralina Ecar is through an official drug take-back program. If a take-back program is unavailable, follow the guidance to mix the medicine with an undesirable substance (such as used coffee grounds) and seal it in a container before placing it in the household trash [FDA Guidance].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sertralina Ecar found in:

A-Z Index: